Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes

Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment...

Full description

Bibliographic Details
Main Authors: Morten Hindsø, Christoffer Martinussen, Maria Saur Svane, Simon Veedfald, Birthe Gade-Rasmussen, Torben Hansen, Sten Madsbad
Format: Article
Language:English
Published: SMC MEDIA SRL 2021-03-01
Series:European Journal of Case Reports in Internal Medicine
Subjects:
neonatal diabetes
kcnj11
sulfonylurea
glp-1
Online Access:https://www.ejcrim.com/index.php/EJCRIM/article/view/2352
id doaj-e1737c5e0a994ba78fd37a9e7ffbbe8e
record_format Article
spelling doaj-e1737c5e0a994ba78fd37a9e7ffbbe8e2021-04-02T07:17:12ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942021-03-0110.12890/2021_0023521968Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal DiabetesMorten Hindsø0Christoffer Martinussen1Maria Saur Svane2Simon Veedfald3Birthe Gade-Rasmussen4Torben Hansen5Sten Madsbad6Department of Endocrinology, Hvidovre Hospital, Hvidovre, DenmarkDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, DenmarkDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, DenmarkDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, DenmarkThe Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Genetics, University of Copenhagen, Copenhagen, DenmarkDepartment of Endocrinology, Hvidovre Hospital, Hvidovre, DenmarkSulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months’ follow-up.https://www.ejcrim.com/index.php/EJCRIM/article/view/2352neonatal diabeteskcnj11sulfonylureaglp-1
collection DOAJ
language English
format Article
sources DOAJ
author Morten Hindsø
Christoffer Martinussen
Maria Saur Svane
Simon Veedfald
Birthe Gade-Rasmussen
Torben Hansen
Sten Madsbad
spellingShingle Morten Hindsø
Christoffer Martinussen
Maria Saur Svane
Simon Veedfald
Birthe Gade-Rasmussen
Torben Hansen
Sten Madsbad
Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
European Journal of Case Reports in Internal Medicine
neonatal diabetes
kcnj11
sulfonylurea
glp-1
author_facet Morten Hindsø
Christoffer Martinussen
Maria Saur Svane
Simon Veedfald
Birthe Gade-Rasmussen
Torben Hansen
Sten Madsbad
author_sort Morten Hindsø
title Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
title_short Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
title_full Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
title_fullStr Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
title_full_unstemmed Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
title_sort successful use of a glp-1 receptor agonist as add-on therapy to sulfonylurea in the treatment of kcnj11 neonatal diabetes
publisher SMC MEDIA SRL
series European Journal of Case Reports in Internal Medicine
issn 2284-2594
publishDate 2021-03-01
description Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months’ follow-up.
topic neonatal diabetes
kcnj11
sulfonylurea
glp-1
url https://www.ejcrim.com/index.php/EJCRIM/article/view/2352
work_keys_str_mv AT mortenhindsø successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
AT christoffermartinussen successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
AT mariasaursvane successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
AT simonveedfald successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
AT birthegaderasmussen successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
AT torbenhansen successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
AT stenmadsbad successfuluseofaglp1receptoragonistasaddontherapytosulfonylureainthetreatmentofkcnj11neonataldiabetes
_version_ 1724171391523094528

Similar Items